Senseonics (SENS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Apr, 2026Executive summary
The annual meeting is scheduled for May 20, 2026, and will be held virtually to enhance accessibility and align with sustainability goals.
Six key proposals are up for vote, including director elections, executive compensation, auditor ratification, an increase in authorized shares, and a new equity incentive plan.
Only stockholders of record as of March 26, 2026, are entitled to vote.
Voting matters and shareholder proposals
Proposals include electing three directors, advisory votes on executive compensation and its frequency, ratification of KPMG LLP as auditor, doubling authorized common shares, and approval of the 2026 Equity Incentive Plan.
The board recommends voting for all proposals and for annual say-on-pay votes.
Shareholders can vote online, by phone, mail, or during the virtual meeting.
Board of directors and corporate governance
The board consists of nine members divided into three classes, with a majority deemed independent under Nasdaq rules.
Leadership structure separates the roles of CEO and independent Chairman.
Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, all composed of independent directors.
Directors are encouraged, but not required, to attend the annual meeting.
Latest events from Senseonics
- 2025 revenue up 60% to $35.3M, with 65–76% growth expected in 2026.SENS
Q4 202529 Apr 2026 - Shareholders will vote on director elections, compensation, share increase, and a new equity plan.SENS
Proxy filing9 Apr 2026 - Key proposals include director elections, share increase, and new equity plan, all board-backed.SENS
Proxy filing6 Apr 2026 - Virtual meeting to vote on directors, compensation, share increase, and new equity plan.SENS
Proxy filing27 Mar 2026 - 2025 guidance projects $34–38M revenue and a doubling of the global patient base.SENS
Q4 202413 Feb 2026 - Q2 2025 revenue up 37% YoY to $6.6M, gross margin at 46.9%, net loss narrowed to $14.5M.SENS
Q2 20253 Feb 2026 - Launching a one-year CGM sensor and expanding partnerships to capture rapid diabetes market growth.SENS
Small-Cap Growth Virtual Investor Conference3 Feb 2026 - Q2 revenue up 18% year-over-year, but losses and funding risks remain as Q4 launch nears.SENS
Q2 20242 Feb 2026 - FDA launch of 365-day CGM spurs demand, but Q3 revenue drops and liquidity risks persist.SENS
Q3 202415 Jan 2026